Just two months after Summit Therapeutics and Akeso announced that the PD-1/VEGF bispecific antibody ivonescimab beat Merck & Co.’s PD-1 blockbuster Keytruda (pembrolizumab) in a Phase III lung cancer trial, Merck announced it will acquire its own PD-1/VEGF bispecific antibody through a licensing deal with Shanghai-based LaNova.
Merck & Co. Jumps Into PD-1/VEGF Bispecific Race With LaNova Deal
The company will in-license LM-299, gaining a PD-1/VEGF bispecific antibody that could help it defend its blockbuster PD-1 franchise against looming competition.
More from Deals
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.
• By
South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.
• By
The obesity market leader is teaming up with China’s United Bio-Technology to develop a product they believe could beat Lilly’s late-stage same-class candidate retatrutide.
More from Therapy Areas
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.